miRagen Therapeutics’s MRG- 106 receives EU Orphan Medicinal Product Designation

miRagen Therapeutics announced that  MRG-106 has received orphan medicinal product designation from European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL). CTCL occurs when certain types of T-cells become cancerous and cause debilitating tumors in the skin and in other parts of the body.

The USFDA granted orphan drug designation to MRG-106 for the treatment of mycosis fungoides, the most common subtype of CTCL.

miRagen President and CEO, William S. Marshall said that the European orphan drug designation for MRG-106 is another regulatory milestone which they believe further validates the medical need for novel therapies in the treatment of CTCL. MRG-106 has now been granted orphan drug designation from the FDA and the EC, and they look forward to continuing to develop this product candidate as a potential therapy for patients suffering from this disease.